Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dystonia update.

S B Bressman1

  • 1Department of Neurology, Beth Israel Medical Center, New York, NY 10033-3314, USA.

Clinical Neuropharmacology
|January 12, 2001
PubMed
Summary
This summary is machine-generated.

Dystonia is a neurological disorder causing sustained muscle spasms. Advances in genetics and molecular biology are improving understanding and treatment of this condition, offering better long-term patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

JIMD reports·2014
Same author

Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Parkinsonism & related disorders·2012
Same author

Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites.

Neurology·2012
Same author

Gender differences in the IL6 -174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson's disease.

Neuroscience letters·2011
Same author

Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Neurology·2011
Same author

Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Neuroscience letters·2011
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Dystonia is characterized by sustained muscle spasms originating from the central nervous system.
  • Recent molecular biology advances have improved understanding of dystonia genetics.
  • Pathophysiological deficits are increasingly recognized as the cause of clinical signs.

Purpose of the Study:

  • To provide a comprehensive overview of dystonia.
  • To highlight advances in understanding dystonia genetics and pathophysiology.
  • To outline current and emerging treatment strategies for dystonia.

Main Methods:

  • Review of recent advances in molecular biology and genetics related to dystonia.
  • Analysis of current pharmacological treatments, including anticholinergic medications and botulinum toxin.

Related Experiment Videos

  • Discussion of levodopa responsiveness in specific dystonia forms.

    • Main Results:

    • Molecular biology and genetics have clarified the origins of various dystonia forms.
    • Pharmacological treatments include anticholinergic drugs and botulinum toxin.
    • Levodopa shows particular efficacy in certain types of dystonia.

    Conclusions:

    • A systematic diagnostic and treatment approach is crucial for optimal dystonia care.
    • Understanding the genetic and pathophysiological basis of dystonia informs treatment strategies.
    • Long-term management of dystonia benefits from a comprehensive evaluation.